Mammary Cell News Volume 10.35 | Sep 6 2018

TOP STORY

Cyclin E Overexpression Sensitizes Triple Negative Breast Cancer to Wee1 Kinase Inhibition

Cyclin E overexpression was enriched in triple negative breast cancers (TNBCs) with high recurrence rates, sensitized TNBC cell lines and patient derived xenograft models to AZD1775, led to CDK2-dependent activation of DNA replication stress pathways and increased Wee1 kinase activity. [Clin Cancer Res] Abstract

(Ranked by impact factor of the journal)

HER2/EGFR-AKT Signaling Switches TGF-β from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Activation of HER2/EGFR induced phosphorylation of Smad3 at Ser208 of the linker region through AKT, which promoted the nuclear accumulation of Smad3 and subsequent expression of the genes related to EMT and cell migration. Knockdown of Smad3, but not Smad2, blocked transforming growth factor-β (TGF-β)-induced breast cancer cell migration. [Cancer Res] Abstract

JMJD6 Regulates Histone H2A.X Phosphorylation and Promotes Autophagy in Triple-Negative Breast Cancer Cells via a Novel Tyrosine Kinase Activity

High jumonji domain-containing 6 (JMJD6) levels promoted autophagy in triple-negative breast cancer (TNBC) cells by regulating the expression of autophagy-related genes. The JMJD6-phosphorylated Y39 of histone H2A.X axis promoted TNBC cell growth via the autophagy pathway. [Oncogene] Abstract

A Mandatory Role of Nuclear PAK4-LIFR Axis in Breast-to-Bone Metastasis of ERα-Positive Breast Cancer Cells

Nuclear p21-activated kinase 4 (nPAK4) enhanced the invasive potential of estrogen receptor alpha (ERα)-positive breast cancer cells in vitro and promoted breast cancer metastasis in vivo. nPAK4 promoted the metastasis of ERα-positive-breast cancer cells by targeting leukemia inhibitory factor receptor (LIFR), a bone metastasis suppressor. [Oncogene] Full Article

CXCL1 Derived from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via Activating NF-κB/SOX4 Signaling

Researchers validated that C-X-C motif chemokine ligand 1 (CXCL1) was the most abundant chemokine secreted by tumor-associated macrophages, and CXCL1 could promote breast cancer migration and invasion ability, as well as epithelial-mesenchymal transition in both mouse and human breast cancer cells. They revealed that CXCL1 bound to SOX4 promoter and activated its transcription via the NF-κB pathway. [Cell Death Dis] Full Article

TiHo-0906: A New Feline Mammary Cancer Cell Line with Molecular, Morphological, and Immunocytological Characteristics of Epithelial to Mesenchymal Transition

Investigators report the establishment and characterization of a cell line exhibiting epithelial-to-mesenchymal transition-like properties derived from a feline mammary carcinoma with anaplastic and malignant spindle cells. [Sci Rep] Full Article

FR58P1a; A New Uncoupler of OXPHOS that Inhibits Migration in Triple-Negative Breast Cancer Cells via Sirt1/AMPK/β1-Integrin Pathway

FR58P1a activated AMPK in a Sirt1-dependent fashion. Prolonged exposure to FR58P1a triggered metabolic reprogramming in triple-negative breast cancer cells characterized by down-regulation of OXPHOS-related genes that promoted cell survival but comprised their ability to migrate. [Sci Rep] Full Article

In Silico Screening for ERα Down Modulators Identifies Thioridazine as an Anti-Proliferative Agent in Primary, 4OH-Tamoxifen-Resistant and Y537S ERα-Expressing Breast Cancer Cells

The authors found that mitoxantrone and thioridazine induced estrogen receptor α (ERα) downmodulation and prevented MCF-7 breast cancer (BC) cell proliferation. While mitoxantrone was found to be toxic for normal breast epithelial cells, thioridazine showed a preferential activity towards BC cells. [Cell Oncol (Dordr)] Abstract

The Oncoprotein HBXIP Promotes Human Breast Cancer Growth through Down-Regulating p53 via miR-18b/MDM2 and pAKT/MDM2 Pathways

Researchers showed that hepatitis B X-interacting protein (HBXIP) could up-regulate MDM2 by inducing DNA methylation of miR-18b, thus suppressing miR-18b expression, leading to the attenuation of p53 in breast cancer cells. [Acta Pharmacol Sin] Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

WNT5A as a Therapeutic Target in Breast Cancer

Investigators focus on the relevance, mechanisms, and therapeutic potential of targeting WNT5A as a future anti-metastatic treatment strategy for breast cancer patients by restoring WNT5A signaling as an innovative therapeutic option. [Cancer Metastasis Rev] Full Article

Epigenomics of Mammary Gland Development

Epigenetic mechanisms such as DNA methylation, post-translational modifications to histone tails, and nucleosome positioning all potentially contribute to the changes in higher order chromatin structure during differentiation. The authors review the current literature surrounding DNA methylation and histone modifications in the developing mammary gland and its implications for breast cancer. [Breast Cancer Res] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Oncodesign Furthers Its Cooperation with Eisai, Started 12 Years Ago

ONCODESIGN announced that it is furthering its cooperation with Eisai Co., Ltd. with the signing of a new services agreement. This services agreement aims to evaluate the anti-tumor efficacy of Eisai new compounds, alone or in combination with standards of care, on a panel of patient-derived xenografts of breast cancer developed specifically by Oncodesign between 2012 and 2017. [ONCODESIGN (Business Wire, Inc.)] Press Release

Health Canada Approves PERJETA^® (Pertuzumab) for the Treatment of HER2-Positive Early Breast Cancer after Surgery

Hoffmann-La Roche Limited announced that Health Canada has approved PERJETA in combination with HERCEPTIN^® and chemotherapy for adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with lymph node positive and/or hormone receptor negative disease. [Hoffmann-La Roche Limited (CNW Group Ltd.)] Press Release

European Commission Grants Marketing Authorization for Puma Biotechnology’s NERLYNX^® (Neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. announced that the European Commission has granted marketing authorization for NERLYNX^® for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. [Puma Biotechnology, Inc.] Press Release

FDA Official Says Trump’s New Limits on Hiring Foreign Scientists Makes It Harder to Attract Top Talent

The Trump administration’s restrictions on hiring foreign scientists are making it more difficult for the agency to attract top scientific talent, a top FDA official said. “[The policy] definitely has created an additional challenge, I think, for us,” said Melanie Keller, the FDA’s acting associate commissioner for scientific and clinical recruitment. [STAT News] Editorial

AACR Apologizes for Delays in Retracting Papers

The American Association for Cancer Research (AACR) has issued retractions, corrections, or editor’s notes for a handful papers across five of its journals and is sorry for the time it’s taken to do so, according to a statement published in Cancer Research. [The Scientist] Editorial

European Science Funders Ban Grantees from Publishing in Paywalled Journals

Frustrated with the slow transition toward open access in scientific publishing, eleven national funding organizations in Europe turned up the pressure. As of 2020, the group, which jointly spends about €7.6 billion on research annually, will require every paper it funds to be freely available from the moment of publication. [ScienceInsider] Editorial

NEW Cell Symposia: Engineering Organoids and Organs
August 25-27, 2019
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine)

Postdoctoral Position – Cancer Biology (GIGA – Universite de Liege)

Research Assistant II – Breast Medical Oncology (MD Anderson Cancer Center)

Cancer Faculty Investigators – Breast Cancer (The University of Alabama)

Tenure-Track Assistant Professor – Breast Cancer Biology (Johns Hopkins University School of Medicine)

Postdoctoral Fellow/Research Scientist – Cancer Research (Icahn School of Medicine at Mount Sinai)

Postdoctoral Positions – Breast Cancer Research (UPMC Hillman Cancer Center)

Cancer Faculty Investigators – Cancer Research (University of Alabama at Birmingham)

Postdoctoral Research Fellow – Immuno/Oncology of Breast Cancer (Henry M. Jackson Foundation)

Research Assistant/Associate – Translational Breast Cancer Research (Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Breast Cancer (University of Trento)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.